Retatrutide
GIP/GLP-1/GCG · s.c. · Eli Lilly
Summary
- Also known as
- LY3437943
- Mechanism
- GIP/GLP-1/GCG
- Route
- s.c.
- Company
- Eli Lilly
- Highest development stage
- phase 3
- Status (as of data cut)
- Phase 3 positive: TRIUMPH-1 (NEJM 2026), TRIUMPH-2/-3 and TRIUMPH-4 toplines; TRANSCEND-T2D-1 at EASD 2026 verify
- Next milestone
- US submission planned Q1 2027
Sources for the status
Indications: regulatory and evidence status
| Indication | Code | Status | Evidence |
|---|---|---|---|
| Obesity | 3 positive phase 3 | Positive phase 3 (TRIUMPH-1 published; TRIUMPH-3 topline); US submission planned Q1 2027 | TRIUMPH-1; TRIUMPH-2/-3 topline, Lilly press release (Jul 2026) |
| T2D | 3 positive phase 3 | Positive phase 3 (TRANSCEND-T2D-1; TRIUMPH-2 HbA1c) | TRANSCEND-T2D-1 (EASD 2026); TRIUMPH-2 topline, Lilly press release (Jul 2026) |
| CV outcomes | 2 phase 3 ongoing | CV and kidney outcomes trial ongoing | TRIUMPH-OUTCOMES |
| CKD | 2 phase 3 ongoing | Phase 3 ongoing | Kidney study in T2D |
| HFpEF | 0 no data | ||
| MASH | 2 phase 3 ongoing | Phase 3 ongoing | |
| Sleep apnoea | 3 positive phase 3 | Positive phase 3: TRIUMPH-1-OSA and TRIUMPH-2-OSA (NEJM 2026) | TRIUMPH-1-OSA / TRIUMPH-2-OSA, NEJM 2026 |
| Knee OA | 3 positive phase 3 | Positive phase 3: TRIUMPH-4 and TRIUMPH-1-OA (NEJM, Nov 2026) | TRIUMPH-4 / TRIUMPH-1-OA, NEJM 2026; TRIUMPH-4 |
| Alzheimer's | 0 no data |
4 = approved / in a label (FDA, EMA or NMPA), 3 = positive phase 3, 2 = phase 3 ongoing or completed without public results, 1 = phase 2 or signal only, 0 = no data, −1 = negative phase 3/4. L = label, P = PubMed, T = registry.
US prescribing information: indications
Verbatim section 1 of the current FDA label (DailyMed), as checked by the atlas.
Trial arms: weight, HbA1c and tolerability
| Trial | Arm | Population | Weeks | n | Weight, efficacy | Weight, treatment-policy | HbA1c, pp | AE discontinuation, % | Any discontinuation, % | Nausea, % | Vomiting, % | SAE, % | SBP, mmHg | Status |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Retatrutide phase 2 (T2D) | retatrutide 12 mg | t2d | 36 | 281 | −16.9 % vs −3.0 % Δ −13.9 pp | — | −2.0 vs +0.0 | — | — | — | — | — | — | seed |
| Retatrutide phase 2 (obesity) | retatrutide 12 mg | obesity | 48 | 338 | −24.2 % vs −2.1 % Δ −22.1 pp | — | — | 16.0 vs 0.0 | — | 45.0 vs 11.0 | 19.0 vs 1.0 | 3.0 vs 4.0 | — | verified |
| Retatrutide phase 2 (obesity) | retatrutide 8 mg (start 4 mg) | obesity | 48 | 338 | −23.9 % vs −2.1 % Δ −21.8 pp | — | — | 6.0 vs 0.0 | — | 60.0 vs 11.0 | 26.0 vs 1.0 | 6.0 vs 4.0 | — | verified |
| Retatrutide phase 2 (obesity) | retatrutide 4 mg (start 4 mg) | obesity | 48 | 338 | −17.8 % vs −2.1 % Δ −15.7 pp | — | — | 9.0 vs 0.0 | — | 36.0 vs 11.0 | 12.0 vs 1.0 | 6.0 vs 4.0 | — | verified |
| TRANSCEND-T2D-1 (T2D monotherapy) | retatrutide 12 mg | t2d | 40 | 537 | −16.8 % vs −2.5 % Δ −14.3 pp | −16.8 % vs −2.5 % Δ −14.3 pp | −1.9 vs −0.8 | 5.1 vs 0.0 | — | — | — | — | — | verified |
| TRANSCEND-T2D-2 (vs semaglutide 2 mg) | retatrutide 9 mg vs semaglutide 2 mg (active) | t2d | 80 | — | −19.5 % | — | −2.2 | 4.8 | — | 21.2 | 10.2 | — | — | press release |
| TRANSCEND-T2D-2 (vs semaglutide 2 mg) | retatrutide 12 mg vs semaglutide 2 mg (active) | t2d | 80 | — | −20.9 % | — | −2.2 | 7.9 | — | 23.8 | 15.0 | — | — | press release |
| TRIUMPH-1 | retatrutide 4 mg | obesity | 80 | 584 | −19.0 % vs −2.2 % Δ −16.8 pp | −17.6 % vs −3.9 % Δ −13.7 pp | — | 4.1 vs 4.6 | — | 28.6 vs 14.8 | 10.6 vs 4.8 | 7.7 vs 5.5 | −7.6 vs −1.9 | verified |
| TRIUMPH-1 | retatrutide 9 mg | obesity | 80 | 584 | −25.9 % vs −2.2 % Δ −23.7 pp | −23.7 % vs −3.9 % Δ −19.8 pp | — | 6.5 vs 4.6 | — | 38.4 vs 14.8 | 22.8 vs 4.8 | 7.7 vs 5.5 | −9.8 vs −1.9 | verified |
| TRIUMPH-1 | retatrutide 12 mg | obesity | 80 | 584 | −28.3 % vs −2.2 % Δ −26.1 pp | −25.0 % vs −3.9 % Δ −21.1 pp | — | 11.2 vs 4.6 | — | 42.4 vs 14.8 | 25.3 vs 4.8 | 10.5 vs 5.5 | −10.4 vs −1.9 | verified |
| TRIUMPH-2 (obesity + T2D) | retatrutide 4 mg | t2d | 80 | — | −12.7 % vs −4.0 % Δ −8.7 pp | −11.9 % vs −5.1 % Δ −6.8 pp | −1.4 vs −0.5 | 3.0 vs 5.0 | 10.3 vs 21.5 | 14.0 vs 8.0 | 6.0 vs 4.0 | 8.0 vs 8.0 | −5.0 vs −2.7 | verified |
| TRIUMPH-2 (obesity + T2D) | retatrutide 9 mg | t2d | 80 | — | −19.1 % vs −4.0 % Δ −15.1 pp | −16.8 % vs −5.1 % Δ −11.7 pp | −1.5 vs −0.5 | 11.0 vs 5.0 | 19.4 vs 21.5 | 21.0 vs 8.0 | 10.0 vs 4.0 | 9.0 vs 8.0 | −7.4 vs −2.7 | verified |
| TRIUMPH-2 (obesity + T2D) | retatrutide 12 mg | t2d | 80 | — | −20.8 % vs −4.0 % Δ −16.8 pp | −18.8 % vs −5.1 % Δ −13.7 pp | −1.4 vs −0.5 | 7.0 vs 5.0 | 13.9 vs 21.5 | 28.0 vs 8.0 | 16.0 vs 4.0 | 9.0 vs 8.0 | −9.7 vs −2.7 | verified |
| TRIUMPH-4 (obesity + knee osteoarthritis) | retatrutide 9 mg | obesity | 68 | 148 | −26.4 % vs −2.1 % Δ −24.3 pp | −20.0 % vs −4.6 % Δ −15.4 pp | — | 12.9 vs 4.0 | — | — | — | 9.5 vs 2.0 | — | verified |
| TRIUMPH-4 (obesity + knee osteoarthritis) | retatrutide 12 mg | obesity | 68 | 148 | −28.7 % vs −2.1 % Δ −26.6 pp | −23.7 % vs −4.6 % Δ −19.1 pp | — | 18.2 vs 4.0 | — | — | — | 10.8 vs 2.0 | −14.0 | verified |
Weight: percent change from baseline, drug vs placebo or comparator, Δ = difference in percentage points. Efficacy estimand = effect while on treatment (hypothetical strategy); treatment-policy = all randomised participants regardless of adherence (ITT). AE discontinuation = stopped study drug for any adverse event. Hover a status for its definition.
Notes
- retatrutide 12 mg: Values to be re-checked: the HbA1c shown is the 24-week value; the available text is an OCR scan (clean PDF requested).
- retatrutide 12 mg: Weight −11.5 % (4 mg) and −15.5 % (9 mg); HbA1c −1.7 to −2.0 % vs −0.8 %. The values shown are the 12 mg arm.
- retatrutide 9 mg: Peer-reviewed paper (NEJM, November 2026): n, treatment-regimen weight, AE discontinuation and SAE from Tables 2–3. Efficacy-estimand weight and SBP still from the December 2025 topline release (Supplementary Tables S8/S11 not yet in hand); nausea and vomiting are in Supplementary Table S12. AE discontinuation: Table 3 gives 19/147 (12.9 %), the Results text 18/148 (12.2 %); the table value is shown.
- retatrutide 12 mg: Peer-reviewed paper (NEJM, November 2026): n, treatment-regimen weight, AE discontinuation and SAE from Tables 2–3. Efficacy-estimand weight and SBP still from the December 2025 topline release (Supplementary Tables S8/S11 not yet in hand); nausea and vomiting are in Supplementary Table S12.
- retatrutide 9 mg: Head-to-head, open-label, vs semaglutide 2 mg: weight −9.4 %, HbA1c −1.8 %-points (efficacy estimand); AE discontinuation 2.7 %, nausea 21.3 %, vomiting 13.2 %. N=1,298 randomised 2:2:1; primary endpoint HbA1c non-inferiority of 12 mg; HbA1c superiority of 9 mg nominal only. Topline release; publication pending.
- retatrutide 12 mg: Head-to-head, open-label, vs semaglutide 2 mg: weight −9.4 %, HbA1c −1.8 %-points (efficacy estimand); AE discontinuation 2.7 %, nausea 21.3 %, vomiting 13.2 %. N=1,298 randomised 2:2:1; primary endpoint HbA1c non-inferiority of 12 mg; HbA1c superiority of 9 mg nominal only. Topline release; publication pending.
Verbatim quotes from the source (85)
- retatrutide 12 mg · ae_dc · Table 3, AEs leading to discontinuation
Any event 0 5 (7) 2 (6) 3 (9) 5 (14) 2 (6) 10 (16) 27 (8)
- retatrutide 12 mg · nausea · Table 3
Nausea 8 (11) 10 (14) 6 (18) 12 (36) 6 (17) 21 (60) 28 (45) 91 (27)
- retatrutide 12 mg · vomiting · Table 3
Vomiting 1 (1) 2 (3) 4 (12) 4 (12) 2 (6) 9 (26) 12 (19) 34 (10)
- retatrutide 12 mg · sae · Table 3
Serious adverse event 3 (4) 3 (4) 0 2 (6) 1 (3) 2 (6) 2 (3) 13 (4)
- retatrutide 12 mg · weight_eff · Results, Changes in Body Weight
−24.2% in the 12-mg group with an initial dose of 2 mg
- retatrutide 8 mg (start 4 mg) · ae_dc · Table 3
8 mg (initial 4 mg): 2 (6%)
- retatrutide 8 mg (start 4 mg) · nausea · Table 3
Nausea 8 (11) 10 (14) 6 (18) 12 (36) 6 (17) 21 (60) 28 (45) 91 (27)
- retatrutide 8 mg (start 4 mg) · vomiting · Table 3
Vomiting 1 (1) 2 (3) 4 (12) 4 (12) 2 (6) 9 (26) 12 (19) 34 (10)
- retatrutide 8 mg (start 4 mg) · sae · Table 3
Serious adverse event 3 (4) 3 (4) 0 2 (6) 1 (3) 2 (6) 2 (3) 13 (4)
- retatrutide 8 mg (start 4 mg) · weight_eff · Results, Changes in Body Weight
−23.9% in the 8-mg group (initial dose 4 mg)
- retatrutide 4 mg (start 4 mg) · ae_dc · Table 3
4 mg (initial 4 mg): 3 (9%)
- retatrutide 4 mg (start 4 mg) · nausea · Table 3
Nausea 8 (11) 10 (14) 6 (18) 12 (36) 6 (17) 21 (60) 28 (45) 91 (27)
- retatrutide 4 mg (start 4 mg) · vomiting · Table 3
Vomiting 1 (1) 2 (3) 4 (12) 4 (12) 2 (6) 9 (26) 12 (19) 34 (10)
- retatrutide 4 mg (start 4 mg) · sae · Table 3
Serious adverse event 3 (4) 3 (4) 0 2 (6) 1 (3) 2 (6) 2 (3) 13 (4)
- retatrutide 4 mg (start 4 mg) · weight_eff · Results, Changes in Body Weight
−17.8% in the 4-mg group with an initial dose of 4 mg
- retatrutide 12 mg · weight_eff · Results
The estimated mean percent change from BL in BW was -11.5% with 4 mg, -15.5% with 9 mg, -16.8% with 12 mg retatrutide vs -2.5% with placebo (all p<0.001).
- retatrutide 12 mg · ae_dc · Results
Discontinuation due to AEs occurred in 2.2% (4 mg), 4.5% (9 mg), and 5.1% (12 mg) participants treated with retatrutide, versus 0% with placebo.
- retatrutide 12 mg · hba1c · Results
The estimated mean change from BL in HbA1c was -1.7% (-18.5 mmol/mol) with 4 mg, -2.0% (-22.0 mmol/mol) with 9 mg, and -1.9% (-21.0 mmol/mol) with 12 mg retatrutide
- retatrutide 4 mg · weight_eff · Results, Body-Weight Outcomes, paragraph 1
The corresponding mean percent changes in body weight from baseline to week 80 for the efficacy-estimand calculation were −19.0%, −25.9%, and −28.3%, as compared with 2.2% with placebo
- retatrutide 4 mg · weight_tp · Results, Body-Weight Outcomes, paragraph 1; Table 2
−17.6% with the 4-mg dose, −23.7% with the 9-mg dose, and −25.0% with the 12-mg dose, as compared with −3.9% with placebo
- retatrutide 4 mg · ae_dc · Table 3
Leading to discontinuation of retatrutide or placebo‡ 24 (4.1) 38 (6.5) 65 (11.2) 27 (4.6)
- retatrutide 4 mg · nausea · Table 3
Nausea 167 (28.6) 224 (38.4) 247 (42.4) 87 (14.8)
- retatrutide 4 mg · vomiting · Table 3
Vomiting 62 (10.6) 133 (22.8) 147 (25.3) 28 (4.8)
- retatrutide 4 mg · sae · Table 3
Serious adverse event 45 (7.7) 45 (7.7) 61 (10.5) 32 (5.5)
- retatrutide 4 mg · sbp · Table 2 (continued)
Change in systolic blood pressure (95% CI) — mm Hg −7.6 (−8.6 to −6.5) −9.8 (−10.8 to −8.7) −10.4 (−11.6 to −9.2) −1.9 (−3.6 to −0.3)
- retatrutide 9 mg · weight_eff · Results, Body-Weight Outcomes, paragraph 1
The corresponding mean percent changes in body weight from baseline to week 80 for the efficacy-estimand calculation were −19.0%, −25.9%, and −28.3%, as compared with 2.2% with placebo
- retatrutide 9 mg · weight_tp · Results, Body-Weight Outcomes, paragraph 1; Table 2
−17.6% with the 4-mg dose, −23.7% with the 9-mg dose, and −25.0% with the 12-mg dose, as compared with −3.9% with placebo
- retatrutide 9 mg · ae_dc · Table 3
Leading to discontinuation of retatrutide or placebo‡ 24 (4.1) 38 (6.5) 65 (11.2) 27 (4.6)
- retatrutide 9 mg · nausea · Table 3
Nausea 167 (28.6) 224 (38.4) 247 (42.4) 87 (14.8)
- retatrutide 9 mg · vomiting · Table 3
Vomiting 62 (10.6) 133 (22.8) 147 (25.3) 28 (4.8)
- retatrutide 9 mg · sae · Table 3
Serious adverse event 45 (7.7) 45 (7.7) 61 (10.5) 32 (5.5)
- retatrutide 9 mg · sbp · Table 2 (continued)
Change in systolic blood pressure (95% CI) — mm Hg −7.6 (−8.6 to −6.5) −9.8 (−10.8 to −8.7) −10.4 (−11.6 to −9.2) −1.9 (−3.6 to −0.3)
- retatrutide 12 mg · weight_eff · Results, Body-Weight Outcomes, paragraph 1
The corresponding mean percent changes in body weight from baseline to week 80 for the efficacy-estimand calculation were −19.0%, −25.9%, and −28.3%, as compared with 2.2% with placebo
- retatrutide 12 mg · weight_tp · Results, Body-Weight Outcomes, paragraph 1; Table 2
−17.6% with the 4-mg dose, −23.7% with the 9-mg dose, and −25.0% with the 12-mg dose, as compared with −3.9% with placebo
- retatrutide 12 mg · ae_dc · Table 3
Leading to discontinuation of retatrutide or placebo‡ 24 (4.1) 38 (6.5) 65 (11.2) 27 (4.6)
- retatrutide 12 mg · nausea · Table 3
Nausea 167 (28.6) 224 (38.4) 247 (42.4) 87 (14.8)
- retatrutide 12 mg · vomiting · Table 3
Vomiting 62 (10.6) 133 (22.8) 147 (25.3) 28 (4.8)
- retatrutide 12 mg · sae · Table 3
Serious adverse event 45 (7.7) 45 (7.7) 61 (10.5) 32 (5.5)
- retatrutide 12 mg · sbp · Table 2 (continued)
Change in systolic blood pressure (95% CI) — mm Hg −7.6 (−8.6 to −6.5) −9.8 (−10.8 to −8.7) −10.4 (−11.6 to −9.2) −1.9 (−3.6 to −0.3)
- retatrutide 9 mg · weight_eff · Article body, paragraph 4
while those on 9 mg lost 26.4%
- retatrutide 9 mg · ae_dc · Schnitzer TJ et al., NEJM 2026 (author accepted manuscript), Table 3
Adverse events 19 27 (18.2) 6 (4.0) 52 (11.7) 4 (2.8) 12 (8.4) 22 (15.3) 9 (6.2) 47 (8.2) leading to (12.9)
- retatrutide 9 mg · weight_tp · Schnitzer TJ et al., NEJM 2026 (author accepted manuscript), Table 2
-20.0 (0.9) -23.7 (1.0) -4.6
- retatrutide 9 mg · sae · Schnitzer TJ et al., NEJM 2026 (author accepted manuscript), Table 3
Serious adverse 14 (9.5) 16 (10.8) 3 (2.0) 33 (7.4) 6 (4.2) 14 (9.8) 21 (14.6) 10 (6.9) 51 (8.9)
- retatrutide 12 mg · weight_eff · Article body, paragraph 4
patients receiving the 12 mg dose losing an average of 28.7% of their body weight
- retatrutide 12 mg · ae_dc · Schnitzer TJ et al., NEJM 2026 (author accepted manuscript), Table 3
Adverse events 19 27 (18.2) 6 (4.0)
- retatrutide 12 mg · sbp · The Phase 3 TRIUMPH-4 Trial, paragraph 3
At the highest dose, systolic blood pressure decreased by 14.0 mm Hg.
- retatrutide 12 mg · weight_tp · Schnitzer TJ et al., NEJM 2026 (author accepted manuscript), Table 2
-20.0 (0.9) -23.7 (1.0) -4.6
- retatrutide 12 mg · sae · Schnitzer TJ et al., NEJM 2026 (author accepted manuscript), Table 3
Serious adverse 14 (9.5) 16 (10.8) 3 (2.0)
- retatrutide 4 mg · weight_eff · Results, paragraph 4 (efficacy estimand)
–12·7% (SE 0·6) in the 4 mg group
- retatrutide 4 mg · weight_tp · Results, paragraph 4; Table 2
was −11·9% (SE 0·6; −12·9 kg [0·6]) with retatrutide 4 mg
- retatrutide 4 mg · ae_dc · Results, paragraph 2; Figure 1
Ten (3%) participants in the retatrutide 4 mg group
- retatrutide 4 mg · disc_any · Figure 1
30 discontinued study drug
- retatrutide 4 mg · nausea · Results, safety paragraph; Table 3
nausea in 40 [14%], 59 [21%], and 80 [28%] vs 23 [8%]
- retatrutide 4 mg · vomiting · Results, safety paragraph; Table 3
in 16 [6%], 29 [10%], and 45 [16%] vs 12 [4%]
- retatrutide 4 mg · sae · Results, safety paragraph; Table 3
Serious adverse events were reported by 24 (8%) in the retatrutide 4 mg group
- retatrutide 4 mg · hba1c · Results, paragraph 6; Table 2
The mean change from baseline to week 80 in HbA1c was −1·38% (SE 0·06) with retatrutide 4 mg
- retatrutide 4 mg · sbp · Results, paragraph 8; Table 2
−5·0 mm Hg [SE 0·7] with 4 mg
- retatrutide 9 mg · weight_eff · Results, paragraph 4 (efficacy estimand)
–19·1% (0·6) in the 9 mg group
- retatrutide 9 mg · weight_tp · Results, paragraph 4; Table 2
−16·8% (0·7; −18·3 kg [0·8]) with retatrutide 9 mg
- retatrutide 9 mg · ae_dc · Results, paragraph 2; Figure 1
31 (11%) in the retatrutide 9 mg group
- retatrutide 9 mg · disc_any · Figure 1
55 discontinued study drug
- retatrutide 9 mg · nausea · Results, safety paragraph; Table 3
nausea in 40 [14%], 59 [21%], and 80 [28%] vs 23 [8%]
- retatrutide 9 mg · vomiting · Results, safety paragraph; Table 3
in 16 [6%], 29 [10%], and 45 [16%] vs 12 [4%]
- retatrutide 9 mg · sae · Results, safety paragraph; Table 3
25 (9%) in the retatrutide 9 mg group
- retatrutide 9 mg · hba1c · Results, paragraph 6; Table 2
−1·50% (0·07) with retatrutide 9 mg
- retatrutide 9 mg · sbp · Results, paragraph 8; Table 2
–7·4 mm Hg [0·8] with 9 mg
- retatrutide 12 mg · weight_eff · Results, paragraph 4 (efficacy estimand)
and –20·8% (0·6) in the 12 mg group
- retatrutide 12 mg · weight_tp · Results, paragraph 4; Table 2
−18·8% (0·7; −20·7 kg [0·8]) with retatrutide 12 mg
- retatrutide 12 mg · ae_dc · Results, paragraph 2; Figure 1
21 (7%) in the retatrutide 12 mg group
- retatrutide 12 mg · disc_any · Figure 1
40 discontinued study drug
- retatrutide 12 mg · nausea · Results, safety paragraph; Table 3
nausea in 40 [14%], 59 [21%], and 80 [28%] vs 23 [8%]
- retatrutide 12 mg · vomiting · Results, safety paragraph; Table 3
in 16 [6%], 29 [10%], and 45 [16%] vs 12 [4%]
- retatrutide 12 mg · sae · Results, safety paragraph; Table 3
27 (9%) in the retatrutide 12 mg group
- retatrutide 12 mg · hba1c · Results, paragraph 6; Table 2
−1·45% (0·07) with retatrutide 12 mg
- retatrutide 12 mg · sbp · Results, paragraph 8; Table 2
−9·7 mm Hg [0·8] with 12 mg
- retatrutide 9 mg · weight_eff · Results, paragraph 2 and efficacy estimand table
Participants taking retatrutide lost an average of 44.3 lbs (19.5%; 9 mg) and 47.4 lbs (20.9%; 12 mg) compared to 20.9 lbs (9.4%) with Ozempic.
- retatrutide 9 mg · ae_dc · Results, adverse events paragraph
Treatment discontinuation rates due to adverse events were 4.8%, 7.9% vs. 2.7% with retatrutide 9 mg and 12 mg vs. Ozempic, respectively.
- retatrutide 9 mg · nausea · Results, adverse events paragraph
nausea (21.2%, 23.8% vs. 21.3%)
- retatrutide 9 mg · vomiting · Results, adverse events paragraph
vomiting (10.2%, 15.0% vs. 13.2%)
- retatrutide 9 mg · hba1c · Results, paragraph 2 and efficacy estimand table
both doses of retatrutide lowered A1C by an average of 2.2% compared to 1.8% with Ozempic at 80 weeks.
- retatrutide 12 mg · weight_eff · Results, paragraph 2 and efficacy estimand table
Participants taking retatrutide lost an average of 44.3 lbs (19.5%; 9 mg) and 47.4 lbs (20.9%; 12 mg) compared to 20.9 lbs (9.4%) with Ozempic.
- retatrutide 12 mg · ae_dc · Results, adverse events paragraph
Treatment discontinuation rates due to adverse events were 4.8%, 7.9% vs. 2.7% with retatrutide 9 mg and 12 mg vs. Ozempic, respectively.
- retatrutide 12 mg · nausea · Results, adverse events paragraph
nausea (21.2%, 23.8% vs. 21.3%)
- retatrutide 12 mg · vomiting · Results, adverse events paragraph
vomiting (10.2%, 15.0% vs. 13.2%)
- retatrutide 12 mg · hba1c · Results, paragraph 2 and efficacy estimand table
both doses of retatrutide lowered A1C by an average of 2.2% compared to 1.8% with Ozempic at 80 weeks.
Outcome trials
Other indications
TRIUMPH-1-OSA / TRIUMPH-2-OSA Retatrutide · Obstructive sleep apnoea + obesity (with or without T2D) · 80 weeks · n = 691 verified
AHI −24.4 (9 mg) and −21.9 (12 mg) events/h vs placebo without T2D; −14.4 and −15.1 with T2D (hybrid estimand, primary). Sub-studies nested in TRIUMPH-1 and TRIUMPH-2.
| Measure | Drug | Control | Difference (95 % CI) | Status |
|---|---|---|---|---|
| Apnea-hypopnea index, change from baseline (hybrid estimand) TRIUMPH-1-OSA, no T2D · 4 mg week 80 | −22.9 | −9.9 | −13.0 (−23.0 to −3.0) events/h | verified |
| Apnea-hypopnea index, change from baseline (hybrid estimand) TRIUMPH-1-OSA, no T2D · 9 mg week 80 | −34.3 | −9.9 | −24.4 (−34.1 to −14.7) events/h | verified |
| Apnea-hypopnea index, change from baseline (hybrid estimand) TRIUMPH-1-OSA, no T2D · 12 mg week 80 | −31.7 | −9.9 | −21.9 (−32.2 to −11.5) events/h | verified |
| Apnea-hypopnea index, change from baseline (hybrid estimand) TRIUMPH-2-OSA, T2D · 4 mg week 80 | −19.2 | −10.3 | −8.9 (−15.9 to −2.0) events/h | verified |
| Apnea-hypopnea index, change from baseline (hybrid estimand) TRIUMPH-2-OSA, T2D · 9 mg week 80 | −24.7 | −10.3 | −14.4 (−21.6 to −7.2) events/h | verified |
| Apnea-hypopnea index, change from baseline (hybrid estimand) TRIUMPH-2-OSA, T2D · 12 mg week 80 | −25.4 | −10.3 | −15.1 (−22.5 to −7.7) events/h | verified |
Verbatim quotes (6)
- Apnea-hypopnea index, change from baseline (hybrid estimand)
−22.9 (−29.7 to −16.0)
- Apnea-hypopnea index, change from baseline (hybrid estimand)
−34.3 (−40.8 to −27.7)
- Apnea-hypopnea index, change from baseline (hybrid estimand)
−31.7 (−38.2 to −25.2)
- Apnea-hypopnea index, change from baseline (hybrid estimand)
−19.2 (−23.7 to −14.7)
- Apnea-hypopnea index, change from baseline (hybrid estimand)
−24.7 (−29.9 to −19.5)
- Apnea-hypopnea index, change from baseline (hybrid estimand)
−25.4 (−30.6 to −20.1)
TRIUMPH-4 / TRIUMPH-1-OA Retatrutide · Knee osteoarthritis + obesity · 68 weeks · n = 1019 verified
WOMAC pain −1.83 (9 mg) and −1.61 (12 mg) points vs placebo on a 0–10 scale at 68 weeks in TRIUMPH-4; −1.35, −1.61 and −1.77 (4/9/12 mg) at 80 weeks in TRIUMPH-1-OA (hybrid-treatment estimand). Weight −15.4 and −19.2 percentage points vs placebo in TRIUMPH-4 (treatment-regimen estimand).
| Measure | Drug | Control | Difference (95 % CI) | Status |
|---|---|---|---|---|
| WOMAC pain (0–10 NRS), change from baseline (hybrid-treatment estimand) TRIUMPH-4 · 9 mg week 68 | −4.0 | −2.1 | −1.8 (−2.4 to −1.3) points | verified |
| WOMAC physical function (0–10 NRS), change from baseline (hybrid-treatment estimand) TRIUMPH-4 · 9 mg week 68 | −3.6 | −1.8 | −1.8 (−2.4 to −1.3) points | verified |
| WOMAC pain (0–10 NRS), change from baseline (hybrid-treatment estimand) TRIUMPH-4 · 12 mg week 68 | −3.7 | −2.1 | −1.6 (−2.2 to −1.1) points | verified |
| WOMAC physical function (0–10 NRS), change from baseline (hybrid-treatment estimand) TRIUMPH-4 · 12 mg week 68 | −3.6 | −1.8 | −1.8 (−2.3 to −1.2) points | verified |
| WOMAC pain (0–10 NRS), change from baseline (hybrid-treatment estimand) TRIUMPH-1-OA · 4 mg week 80 | −3.2 | −1.9 | −1.4 (−1.9 to −0.8) points | verified |
| WOMAC physical function (0–10 NRS), change from baseline (hybrid-treatment estimand) TRIUMPH-1-OA · 4 mg week 80 | −3.2 | −1.5 | −1.7 (−2.2 to −1.1) points | verified |
| WOMAC pain (0–10 NRS), change from baseline (hybrid-treatment estimand) TRIUMPH-1-OA · 9 mg week 80 | −3.5 | −1.9 | −1.6 (−2.2 to −1.0) points | verified |
| WOMAC physical function (0–10 NRS), change from baseline (hybrid-treatment estimand) TRIUMPH-1-OA · 9 mg week 80 | −3.4 | −1.5 | −1.9 (−2.5 to −1.3) points | verified |
| WOMAC pain (0–10 NRS), change from baseline (hybrid-treatment estimand) TRIUMPH-1-OA · 12 mg week 80 | −3.6 | −1.9 | −1.8 (−2.3 to −1.2) points | verified |
| WOMAC physical function (0–10 NRS), change from baseline (hybrid-treatment estimand) TRIUMPH-1-OA · 12 mg week 80 | −3.5 | −1.5 | −1.9 (−2.5 to −1.4) points | verified |
Verbatim quotes (10)
- WOMAC pain (0–10 NRS), change from baseline (hybrid-treatment estimand)
was -3.96 with 9-mg, -3.74 with 12-mg retatrutide, and -2.12 with placebo (estimated treatment difference [ETD] vs. placebo [95% CI]: 9-mg: -1.83 [-2.37,-1.30];
- WOMAC physical function (0–10 NRS), change from baseline (hybrid-treatment estimand)
Physical Function score (0.22) (0.22) Treatment comparison -1.83 (-2.40, - -1.77 (-2.34, - __
- WOMAC pain (0–10 NRS), change from baseline (hybrid-treatment estimand)
12-mg: -1.61 [-2.16,-1.07], all p<0.001; Table 2, Fig. 1)
- WOMAC physical function (0–10 NRS), change from baseline (hybrid-treatment estimand)
-3.64 (0.20) -3.57 (0.20) -1.80 -3.21 (0.18) -3.42 (0.21) -3.48 (0.19) -1.53
- WOMAC pain (0–10 NRS), change from baseline (hybrid-treatment estimand)
baseline to week 80 was -3.22 (4-mg) [key secondary endpoint], -3.48 (9-mg), and -3.64 (12- mg) and -1.87 (placebo) (ETD vs. placebo [95% CI]: 4-mg: -1.35 [-1.92,-0.78]; 9-mg: -1.61 [- 2.20,-1.02]; 12-mg: -1.77 [-2.34,-1.20]; all p<0.001; Table 2, Fig. 1)
- WOMAC physical function (0–10 NRS), change from baseline (hybrid-treatment estimand)
-3.64 (0.20) -3.57 (0.20) -1.80 -3.21 (0.18) -3.42 (0.21) -3.48 (0.19) -1.53
- WOMAC pain (0–10 NRS), change from baseline (hybrid-treatment estimand)
baseline to week 80 was -3.22 (4-mg) [key secondary endpoint], -3.48 (9-mg), and -3.64 (12- mg) and -1.87 (placebo) (ETD vs. placebo [95% CI]: 4-mg: -1.35 [-1.92,-0.78]; 9-mg: -1.61 [- 2.20,-1.02]; 12-mg: -1.77 [-2.34,-1.20]; all p<0.001; Table 2, Fig. 1)
- WOMAC physical function (0–10 NRS), change from baseline (hybrid-treatment estimand)
-3.64 (0.20) -3.57 (0.20) -1.80 -3.21 (0.18) -3.42 (0.21) -3.48 (0.19) -1.53
- WOMAC pain (0–10 NRS), change from baseline (hybrid-treatment estimand)
baseline to week 80 was -3.22 (4-mg) [key secondary endpoint], -3.48 (9-mg), and -3.64 (12- mg) and -1.87 (placebo) (ETD vs. placebo [95% CI]: 4-mg: -1.35 [-1.92,-0.78]; 9-mg: -1.61 [- 2.20,-1.02]; 12-mg: -1.77 [-2.34,-1.20]; all p<0.001; Table 2, Fig. 1)
- WOMAC physical function (0–10 NRS), change from baseline (hybrid-treatment estimand)
-3.64 (0.20) -3.57 (0.20) -1.80 -3.21 (0.18) -3.42 (0.21) -3.48 (0.19) -1.53
Ongoing outcome trials
| Trial | Molecule | Population | Primary endpoint | n | Registry status | Primary completion | Registry |
|---|---|---|---|---|---|---|---|
| TRIUMPH-OUTCOMES | Retatrutide | Obesity + CVD Obesity (BMI ≥27) + ASCVD, with or without T2D | MACE | 10000 | active not recruiting | 2029-02 | NCT06383390 |
Registered trials (15)
From ClinicalTrials.gov and the atlas registry sweep; phase 3 and outcome trials first.
| Trial | Indication | Phase | Status | Start → primary completion | n | Result | Registry |
|---|---|---|---|---|---|---|---|
| TRIUMPH-9 A Study of Retatrutide (LY3437943) in Participants Without Type 2 Diabetes Who Have Obesity or Overweight | Obesity | Phase 3 | active not recruiting | 2026-01 → 2028-10 | 600 | active not recruiting | NCT07357415 |
| TRIUMPH-8 A Study of Retatrutide (LY3437943) in Participants With Obesity or Overweight | Obesity | Phase 3 | active not recruiting | 2025-11 → 2027-06 | 250 | active not recruiting | NCT07232719 |
| SYNERGY-Outcomes A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes) | MASH | Phase 3 | recruiting | 2025-10 → 2030-08 | 4500 | recruiting | NCT07165028 |
| TRIUMPH-7 A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight and Chronic Low Back Pain | Obesity | Phase 3 | active not recruiting | 2025-05 → 2027-09 | 586 | active not recruiting | NCT07035093 |
| TRIUMPH-6 A Study of Retatrutide (LY3437943) in the Maintenance of Weight Reduction in Individuals With Obesity | Obesity | Phase 3 | active not recruiting | 2025-03 → 2028-04 | 643 | active not recruiting | NCT06859268 |
| TRIUMPH-5 A Study of Retatrutide (LY3437943) Compared to Tirzepatide (LY3298176) in Adults Who Have Obesity | Obesity | Phase 3 | active not recruiting | 2024-11 → 2026-11 | 800 | active not recruiting | NCT06662383 |
| TRIUMPH-OUTCOMES The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes) | CV outcomes | Phase 3 | active not recruiting | 2024-04 → 2029-02 | 10000 | NCT06383390 | |
| TRANSCEND-T2D-1 Effect of Retatrutide Compared With Placebo in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise Alone (TRANSCEND-T2D-1) | T2D | Phase 3 | completed | 2024-04 → 2026-01 | 537 | Completed; arm-level results are in the atlas maps (Effect vs cost, Arms) | NCT06354660 |
| TRANSCEND-T2D-3 Effect of Retatrutide Compared With Placebo in Participants With Type 2 Diabetes and Moderate or Severe Renal Impairment, With Inadequate Glycemic Control on Basal Insulin, With or Without Metformin and/or SGLT2 Inhibitor (TRANSCEND-T2D-3) | T2D | Phase 3 | active not recruiting | 2024-03 → 2026-10 | 320 | active not recruiting | NCT06297603 |
| TRANSCEND-T2D-2 Effect of Retatrutide Compared With Semaglutide in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin With or Without SGLT2 Inhibitor (TRANSCEND-T2D-2) | T2D | Phase 3 | active not recruiting | 2024-02 → 2026-08 | 1250 | Primary endpoint met (HbA1c non-inferiority of 12 mg vs semaglutide 2 mg): HbA1c −2.2 (9 and 12 mg) vs −1.8 %-points, weight −19.5 / −20.9 % vs −9.4 % at 80 weeks (efficacy estimand); topline press release, Oct 2026 | NCT06260722 |
| TRIUMPH-4 / TRIUMPH-1-OA A Study of Retatrutide (LY3437943) Once Weekly in Participants Who Have Obesity or Overweight and Osteoarthritis of the Knee | CV outcomes | Phase 3 | completed | 2023-08 → 2025-11 | 445 | Completed; results not yet public | NCT05931367 |
| TRIUMPH-1 A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight | Obesity | Phase 3 | completed | 2023-07 → 2026-04 | 2335 | Completed; arm-level results are in the atlas maps (Effect vs cost, Arms) | NCT05929066 |
| TRIUMPH-2 A Study of Retatrutide (LY3437943) in Participants With Type 2 Diabetes Mellitus Who Have Obesity or Overweight | Obesity | Phase 3 | completed | 2023-07 → 2026-06 | 1152 | Completed; arm-level results are in the atlas maps (Effect vs cost, Arms) | NCT05929079 |
| NCT05936151 A Study of Retatrutide (LY3437943) on Renal Function in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes | CKD | Phase 2 | completed | 2023-07 → 2025-10 | 146 | Completed; results not in the atlas yet | NCT05936151 |
| TRIUMPH-3 A Study of Retatrutide (LY3437943) in Participants With Obesity and Cardiovascular Disease | Obesity | Phase 3 | completed | 2023-05 → 2026-04 | 1946 | Completed; results not in the atlas yet | NCT05882045 |
Primary sources
- Jastreboff AM, Kaplan LM, Frías JP, Wu Q, Du Y, Gurbuz S, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial. N Engl J Med. 2023;389(6):514-526. PMID: 37366315.
- Eli Lilly and Company. A Phase 2 Study of Once-Weekly LY3437943 Compared With Placebo in Participants Who Have Obesity or Are Overweight With Weight-Related Comorbidities. ClinicalTrials.gov identifier NCT04881760. Bethesda (MD): National Library of Medicine. Available from: https://clinicaltrials.gov/study/NCT04881760
- Rosenstock J, Frias J, Jastreboff AM, Du Y, Lou J, Gurbuz S, et al. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA. Lancet. 2023;402(10401):529-544. PMID: 37385280.
- Harpreet S. Bajaj et al. Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist in patients with type 2 diabetes treated with diet and exercise alone (TRANSCEND-T2D-1). Abstract 15. EASD 2026 Annual Meeting; 2026 Sep 29–Oct 3; Milan. [Session: OP 03 GLP-1 and friends: new clinical insights]
- Jastreboff AM, Kaplan LM, Davies MJ, Wilding JPH, Ahmad NN, Murray M, et al. Retatrutide, a Triple Hormone Receptor Agonist, for Treatment of Obesity. N Engl J Med. 2026. PMID: 42814954.
- Schnitzer TJ, Hunter DJ, Conaghan PG, Sharma AM, Pedersen SD, Chen K, et al. Retatrutide Once Weekly in Adults with Knee Osteoarthritis Pain and Obesity. N Engl J Med. 2026. PMID: 43001755.
- Eli Lilly and Company. TRIUMPH-4 topline results [press release coverage]. 2025 Dec 11. Available from: https://www.pharmexec.com/view/lilly-retatrutide-positive-topline-results-successful-phase-iii-trial
- Retatrutide achieves up to 28.7% weight loss and marked knee pain reduction in phase 3 TRIUMPH-4 trial. Patient Care. 2025 Dec 11. Available from: https://www.patientcareonline.com/view/retatrutide-achieves-up-to-28-7-weight-loss-and-marked-knee-pain-reduction-in-phase-3-triumph-4-trial
- Bellido V, le Roux CW, Ekinci EI, Bjornstad P, Frias JP, Giblin K, et al. Retatrutide in adults with obesity and type 2 diabetes (TRIUMPH-2): a double-blind, parallel-group, randomised, placebo-controlled, phase 3 trial. Lancet. 2026;408(10563):1455-1472. PMID: 42810372.
- Eli Lilly and Company. Lilly's retatrutide delivered greater A1C reduction and more than double the weight loss of Ozempic's highest approved dose in head-to-head trial [press release]. Indianapolis (IN): Eli Lilly and Company; 2026 Oct 28. Available from: https://www.prnewswire.com/news-releases/lillys-retatrutide-delivered-greater-a1c-reduction-and-more-than-double-the-weight-loss-of-ozempics-highest-approved-dose-in-head-to-head-trial-302921328.html
- Grunstein RR, Somers VK, Azarbarzin A, Malhotra A, Sands SA, Lucey BP, et al. Retatrutide Once Weekly for Treatment of Obstructive Sleep Apnea. N Engl J Med. 2026. PMID: 42904878.
- Eli Lilly and Company. A Phase 3 Study to Investigate the Efficacy and Safety of LY3437943 Once Weekly in Participants Who Have Obesity or Overweight and Osteoarthritis of the Knee: A Randomized, Double-Blind, Placebo-Controlled Trial (TRIUMPH-4). ClinicalTrials.gov identifier NCT05931367. Bethesda (MD): National Library of Medicine. Available from: https://clinicaltrials.gov/study/NCT05931367
- Eli Lilly and Company. A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Event-Driven Study to Investigate the Effect of Retatrutide on the Incidence of Major Adverse Cardiovascular Events and Major Adverse Kidney Events in Participants With Body Mass Index ≥27 kg/m2 and Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease. ClinicalTrials.gov identifier NCT06383390. Bethesda (MD): National Library of Medicine. Available from: https://clinicaltrials.gov/study/NCT06383390
How to cite this page
Cite the primary publication for any single result; every value above links to it.